id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-D-0369-0279,FDA,FDA-2007-D-0369,Marc Bloomenstein (Schwartz Laser Eye Center) - Letter,Other,Letter(s),2013-12-12T05:00:00Z,2013,12,2013-12-12T05:00:00Z,,2013-12-12T17:47:56Z,,0,0,090000648147aac5
FDA-2007-D-0369-0278,FDA,FDA-2007-D-0369,Supplement from Alison Manson (Prevent Blindness America),Other,Supplement (SUP),2013-12-12T05:00:00Z,2013,12,2013-12-12T05:00:00Z,,2014-11-17T17:35:28Z,,0,0,090000648147aac6
FDA-2007-D-0369-0277,FDA,FDA-2007-D-0369,Draft Guidance for Industry; Availability: Bioequivalence Recommendations for Paliperidone Palmitate Extended-Release Injectable Suspension,Notice,Notice of Availability,2013-12-05T05:00:00Z,2013,12,2013-12-05T05:00:00Z,2014-02-04T04:59:59Z,2014-02-13T02:02:08Z,2013-29080,0,0,09000064814a9e1e
FDA-2007-D-0369-0275,FDA,FDA-2007-D-0369,Draft Guidance for Industry on Bioequivalence Recommendations for Fluticasone Propionate; Salmeterol Xinafoate; Reopening of the Comment Period,Notice,Notice of Availability,2013-11-27T05:00:00Z,2013,11,2013-11-27T05:00:00Z,2013-12-12T04:59:59Z,2013-12-08T18:23:54Z,2013-28394,0,0,090000648149c332
FDA-2007-D-0369-0267,FDA,FDA-2007-D-0369,Draft Guidance for Industry on Bioequivalence Recommendations for Iron Sucrose; Availability,Notice,Notice of Availability,2013-11-06T05:00:00Z,2013,11,2013-11-06T05:00:00Z,2014-01-07T04:59:59Z,2014-01-08T02:03:00Z,2013-26570,0,0,09000064814724f9
FDA-2007-D-0369-0268,FDA,FDA-2007-D-0369,Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,Notice,Notice of Availability,2013-11-06T05:00:00Z,2013,11,2013-11-06T05:00:00Z,2014-01-07T04:59:59Z,2013-12-07T21:29:25Z,2013-26546,0,0,090000648147267c
FDA-2007-D-0369-0264,FDA,FDA-2007-D-0369,"Aptalis Pharma US, Inc. - Request for Extension of Comment Period",Other,Request for Extension,2013-10-30T04:00:00Z,2013,10,2013-10-30T04:00:00Z,,2013-10-30T15:56:37Z,,0,0,090000648142e65c
FDA-2007-D-0369-0261,FDA,FDA-2007-D-0369,Draft Guidance for Industry on Bioequivalence Recommendations for Fluticasone Propionate; Salmeterol Xinafoate; Availability,Notice,Notice of Availability,2013-09-10T04:00:00Z,2013,9,2013-09-10T04:00:00Z,2013-11-27T04:59:59Z,2013-11-20T02:04:23Z,2013-21892,0,0,09000064813ebb62
FDA-2007-D-0369-0244,FDA,FDA-2007-D-0369,Draft Guidance for Industry; Bioequivalence Recommendations for Risperidone Injection; Availability,Notice,Guidance,2013-08-26T04:00:00Z,2013,8,2013-08-26T04:00:00Z,2013-10-26T03:59:59Z,2013-10-29T01:02:08Z,2013-20696,0,0,09000064813c3adb
FDA-2007-D-0369-0235,FDA,FDA-2007-D-0369,Draft Guidance for Industry on Bioequivalence Recommendations for Mesalamine Rectal Suppositories; Availability,Notice,Notice of Data Availability,2013-08-02T04:00:00Z,2013,8,2013-08-02T04:00:00Z,2013-10-02T03:59:59Z,2013-12-28T03:16:34Z,2013-18629,0,0,090000648138c7e7
FDA-2007-D-0369-0229,FDA,FDA-2007-D-0369,Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,Notice,Notice of Availability,2013-06-20T04:00:00Z,2013,6,2013-06-20T04:00:00Z,2013-08-20T03:59:59Z,2013-08-28T01:02:26Z,2013-14675,0,0,0900006481334132
FDA-2007-D-0369-0117,FDA,FDA-2007-D-0369,Draft and Revised Draft Guidances; Availability: Product-Specific Bioequivalence Recommendations re FDA-2007-D-0369-0110,Notice,Notice of Availability,2013-04-08T04:00:00Z,2013,4,2013-04-08T04:00:00Z,2013-06-08T03:59:59Z,2013-06-12T01:01:25Z,2013-08013,0,0,0900006481280145
FDA-2007-D-0369-0116,FDA,FDA-2007-D-0369,Draft Guidance for Industry; Bioequivalence Recommendations for Metronidazole Vaginal Gel,Other,Guidance,2013-04-01T04:00:00Z,2013,4,2013-04-01T04:00:00Z,,2024-11-12T05:14:52Z,,1,0,0900006481253931
FDA-2007-D-0369-0115,FDA,FDA-2007-D-0369,Draft Guidance for Industry; Availability: Bioequivalence Recommendations for Metronidazole Vaginal Gel,Notice,Notice of Availability,2013-03-29T04:00:00Z,2013,3,2013-03-29T04:00:00Z,2013-05-29T03:59:59Z,2013-03-29T13:32:00Z,2013-07296,0,0,090000648124f0dd
FDA-2007-D-0369-0112,FDA,FDA-2007-D-0369,Osmotica Pharmaceutical - Supplemental,Supporting & Related Material,Studies and Reports,2013-03-11T04:00:00Z,2013,3,,,2013-03-11T19:11:39Z,,0,0,0900006481213ece
FDA-2007-D-0369-0110,FDA,FDA-2007-D-0369,Guidance for Industry: Bioequivalence Recommendations for Specific Products,Other,Guidance,2013-02-27T05:00:00Z,2013,2,2013-02-27T05:00:00Z,,2013-05-14T18:39:29Z,,0,0,0900006480f985f0
FDA-2007-D-0369-0109,FDA,FDA-2007-D-0369,Sun Pharmaceutical Industries Ltd. - Supplemental,Other,Supplement (SUP),2013-02-15T05:00:00Z,2013,2,2013-02-15T05:00:00Z,,2013-02-26T00:37:54Z,,0,0,09000064811e5678
FDA-2007-D-0369-0107,FDA,FDA-2007-D-0369,Vifor Pharma Ltd (Sidley Austin LLP) - Supplement re FDA-2007-D-0369-0089,Other,Supplemental Comment,2013-01-23T05:00:00Z,2013,1,2013-01-23T05:00:00Z,,2013-01-23T16:35:34Z,,0,0,09000064811c2961
FDA-2007-D-0369-0105,FDA,FDA-2007-D-0369,Electronic Comment from Surgical Migraine Clinic,Supporting & Related Material,Electronic Comment (EC),2013-01-15T05:00:00Z,2013,1,,,2015-03-13T04:25:11Z,,0,0,090000648042bb8d